6HV1.F Rezolute, Inc.

Healthcare Biotechnology Frankfurt Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 6HV1.F undervalued?

Graham number

The Graham number of Rezolute, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rezolute, Inc. fundamental analysis

No fundamental analysis for Rezolute, Inc. yet.

Rezolute, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, In…

Full company profile